AI drug discovery advances but data quality remains critical bottleneck

Insilico's rentosertib in Phase III, Chai Discovery's $400M raise, Isomorphic Labs entering human trials, but concerns about data quality and only 10-15% of human biology known. New roadmap emphasizes data generation. Pathos AI's $2.3B deals for AI-driven trial design add a new dimension. Daphne Koller highlights target selection as key failure point.